Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Cocrystal Pharma, Inc. (COCP) had Return on Tangible Equity of -139.49% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-8.83M |
|
-- |
|
-- |
|
$9.02M |
|
$-9.02M |
|
$0.19M |
|
$-8.83M |
|
$-8.83M |
|
$-8.83M |
|
$-8.83M |
|
$-8.83M |
|
$-8.83M |
|
$-9.02M |
|
$-8.64M |
|
11.29M |
|
11.29M |
|
$-0.78 |
|
$-0.78 |
|
| Balance Sheet Financials | |
$8.13M |
|
$0.09M |
|
$1.58M |
|
$9.71M |
|
$2.21M |
|
-- |
|
$1.17M |
|
$3.38M |
|
$6.33M |
|
$6.33M |
|
$6.33M |
|
13.78M |
|
| Cash Flow Statement Financials | |
$-8.19M |
|
$-0.01M |
|
$5.37M |
|
$9.94M |
|
$7.10M |
|
$-2.83M |
|
$0.27M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.68 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.20M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-139.49% |
|
|
Return on Tangible Equity |
-139.49% |
-90.93% |
|
-139.49% |
|
$0.46 |
|
$-0.73 |
|
$-0.73 |
|